FDA Suspends Ban on Juul E-cigarette Sales

Jul.13.2022
FDA Suspends Ban on Juul E-cigarette Sales
The FDA temporarily suspends ban on Juul sales for extra review, but concerns over health risks persist.

The US Food and Drug Administration (FDA) has suspended its ban on the sale of Juul Labs' e-cigarettes, stating that additional scrutiny is required for the company's marketing application. Following Juul's appeal for an urgent review of the FDA's order, the federal appeals court decided to temporarily freeze the FDA's ban a few weeks ago.


However, this once flourishing company still remains in a difficult situation: the US Food and Drug Administration has only temporarily halted the re-evaluation ban, it has not been lifted.


Juul has been in the limelight in part due to its prominent position in the e-cigarette industry. However, as the company faces potential extinction, it may become the first casualty while the rest of the e-cigarette industry comes under increasing government scrutiny.


Dr. Zubair Karim, an assistant professor in the Department of Interdisciplinary Health Sciences at Augusta University, conducted research on Juul e-cigarettes and their potential to increase the risk of blood clots and other complications in users.


According to Karim, thrombosis is the partial or complete blockage of blood vessels, whether it occurs in veins or arteries, which restricts the natural flow of blood.


According to the location of blood clot formation, there are several potential complications. The most severe issues include stroke, heart attack, and a serious respiratory condition known as pulmonary embolism. Without prompt treatment, these conditions can be life-threatening. However, by focusing on lifestyle changes such as increasing physical activity, quitting smoking, losing weight, maintaining a balanced diet, avoiding junk food, and managing other health conditions, it is possible to prevent the disease from advancing.


As a ban on Juul products looms, it could lead to a ban on other companies' electronic cigarette products.


Karim stated, "This is the first step in banning e-cigarettes, and the FDA has taken an important and bold move.


Gradually, this will pave the way for the banning of other e-cigarette products. Juul and other products are no different, but Juul is becoming increasingly popular among our younger generation. Many localities and states have recently begun implementing laws banning the use of e-cigarettes, although some states with comprehensive smoke-free laws will still allow the use of e-cigarettes in bars and restaurants while prohibiting their use in other indoor venues.


For years, electronic cigarettes and their devices have been considered a "safer" alternative to traditional cigarettes, but their flavors and packaging have attracted children, and there are renewed efforts to study their possible side effects.


Looking at the long-term effects, both smoking and vaping have similar side effects and pose serious health risks. Scientists do not fully understand the long-term impact of vaping on health, but studies show that electronic cigarettes are not a safe alternative to smoking," said Karim.


In recent years, it has been observed that electronic cigarettes are becoming increasingly popular among young people. Additionally, electronic cigarettes contain high doses of nicotine, which is known to slow the development of fetuses, children, and adolescents' brains. Furthermore, electronic cigarettes involve inhaling aerosols that contain multiple chemicals, including those used for flavoring via electronic cigarettes or other devices. Additionally, the liquid produced in electronic cigarettes can be hazardous if swallowed, inhaled, or applied topically to the skin for both adults and children.


Despite this, e-cigarettes still contain harmful chemicals such as diacetyl, carcinogens, heavy metals, volatile organic compounds, and toxic chemicals not found in traditional cigarettes. In summary, the long-term toxic effects of e-cigarette use on overall health are similar to those of traditional cigarettes.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

Australia Adds 6-Methylnicotine to Schedule 9 Prohibited Substances, Effective October 1
Australia Adds 6-Methylnicotine to Schedule 9 Prohibited Substances, Effective October 1
Australia's Therapeutic Goods Administration published a final decision on September 25 to classify 6-methylnicotine as a Schedule 9 prohibited substance under the Poisons Standard, effective October 1, 2026. TGA said the chemical has been reported in e-cigarette liquids sold in Australia and marketed as nicotine-free or nicotine alternatives, while evidence also indicates its use in preparations such as oral pouches. The government originally proposed a Schedule 7 classification but ultimately adopted the stricter Schedule 9 designation, citing acute toxicity, dependence risk, use in unapproved consumer products and misleading marketing.
News
Sep.29 by 2Firsts Perspectives
China Tobacco Supply-Chain Leader Huabao’s Three-Way Transformation Takes Hold as Overseas Revenue Jumps 216%, Non-Flavor Businesses Reach 42.2% and the Company Expands Into Global Next-Generation Tobacco Supply Chains
China Tobacco Supply-Chain Leader Huabao’s Three-Way Transformation Takes Hold as Overseas Revenue Jumps 216%, Non-Flavor Businesses Reach 42.2% and the Company Expands Into Global Next-Generation Tobacco Supply Chains
Huabao’s H1 2026 results show the company advancing across three connected fronts: international expansion, entry into next-generation tobacco supply chains and diversification beyond its traditional tobacco-related base. Overseas revenue rose 216.08% to CNY 96.02 million, while non-flavor businesses reached 42.2% of total revenue. Huabao also said it had entered the supply chains of leading global tobacco customers, as its nutrition, food ingredient, fragrance and personal-care businesses gained ground in Europe, Southeast Asia, Australia and New Zealand. However, adjusted net profit increased only 2.78%, and next-generation tobacco revenue was not separately disclosed, showing that the transformation is reshaping revenue and customer exposure but has yet to translate fully into underlying earnings.
Aug.28
Product | DOJO Launches 0+6ml BLAST7K Fresh in UK in September, Retaining 2+8ml Pod Compatibility Ahead of October Per-Milliliter Vaping Duty
Product | DOJO Launches 0+6ml BLAST7K Fresh in UK in September, Retaining 2+8ml Pod Compatibility Ahead of October Per-Milliliter Vaping Duty
DOJO officially launched the BLAST7K Fresh on September 17, 2026, introducing a UK-market prefilled pod product with 6ml of e-liquid and a manufacturer-rated capacity of up to 7,000 puffs. The device features a 1000mAh rechargeable battery, the INSTA-JUICED structure and COREX BLAST dual-mesh technology, while retaining compatibility with existing BLAST pods. The launch comes less than two weeks before the UK's Vaping Products Duty takes effect on October 1. At the new duty rate, 6ml of vaping liquid would correspond to £1.32 in VPD. DOJO has not stated that the product's 6ml format was designed in response to the new duty.
Sep.20
Elf Bar Vape Explosion and Amputation Claim Spurs Coverage Suit, U.S. Insurer MUSIC Seeks Ruling It Owes No Duty to Defend or Indemnify Distributor i5
Elf Bar Vape Explosion and Amputation Claim Spurs Coverage Suit, U.S. Insurer MUSIC Seeks Ruling It Owes No Duty to Defend or Indemnify Distributor i5
Mesa Underwriters Specialty Insurance Company has asked a federal court in Washington to declare that it has no duty to defend or indemnify vape distributor i5 Distribution in a product liability case involving an Elf Bar BC5000. The plaintiff alleges that the disposable vape caught fire and exploded in his pocket, causing severe burns and ultimately requiring an above-the-knee amputation of his left leg. MUSIC is relying on a tobacco, nicotine or nicotine replacement products exclusion and a premises limitation endorsement. The court has not ruled on the coverage dispute.
News
Sep.10
Product | JT Launches Three Autumn-Limited Ploom Tobacco Sticks in Japan Across EVO, MEVIUS and CAMEL Brands
Product | JT Launches Three Autumn-Limited Ploom Tobacco Sticks in Japan Across EVO, MEVIUS and CAMEL Brands
Japan Tobacco Inc. (JT) launched three limited-edition autumn tobacco sticks for its Ploom heated tobacco devices in Japan on October 16, 2026, under the EVO, MEVIUS and CAMEL brands. All three are regular tobacco variants with seasonal packaging. Each pack contains 20 sticks, priced at ¥620, ¥590 and ¥570, respectively, including tax. The products are compatible with all Ploom devices and are sold in limited quantities exclusively through the CLUB JT online store while supplies last.
product
Oct.20
Canada Health Minister Says She Is Not Considering Looser Nicotine Pouch Retail Rules as PMI-Linked Group Pushes for Wider Access
Canada Health Minister Says She Is Not Considering Looser Nicotine Pouch Retail Rules as PMI-Linked Group Pushes for Wider Access
Canadian Health Minister Marjorie Michel says she is not considering loosening retail restrictions on nicotine pouches. Canada regulates pouches containing 4 mg or less of nicotine per unit as non-prescription nicotine replacement therapy and requires newer NRT formats such as pouches to be sold from behind pharmacy counters. Meanwhile, Unsmoke Canada, linked to Philip Morris International's Canadian business, is pushing to allow pouches in convenience stores and other general retail outlets. Health Canada also acknowledges continued unauthorized sales, while recent research shows rising pouch use among Canadian youth aged 16 to 19.
Sep.24